Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ERN1 | O75460 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | USP10 | Q14694 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436487 | 1.00 | VCAM1 (0.43) | VCAM1KMT2ASLC10A6KDM4EERN1 | |
| SCHEMBL573281 | 0.87 | VCAM1 (0.45) | VCAM1KMT2ASLC10A6KDM4EERN1 | |
| SCHEMBL573280 | 0.87 | VCAM1 (0.45) | VCAM1KMT2ASLC10A6KDM4EERN1 | |
| SCHEMBL11000444 | 0.87 | VCAM1 (0.44) | VCAM1KMT2AERN1ALDH1A1USP10 | |
| SCHEMBL11000446 | 0.87 | VCAM1 (0.44) | VCAM1KMT2AERN1ALDH1A1USP10 | |
| SCHEMBL11197357 | 0.84 | KDM4E (0.37) | KMT2AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL21436402 | 0.84 | KDM4E (0.37) | KMT2AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL573293 | 0.81 | VCAM1 (0.47) | VCAM1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL573292 | 0.81 | VCAM1 (0.47) | VCAM1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL21436403 | 0.78 | KDM4E (0.35) | KMT2AKDM4EALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112969692-A | Bumetanide derivatives for the treatment of hyperhidrosis | 兹伦汀公司 | 2021-06-15 | — | — | CN | disclosed |
| EP-3774763-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | ZILENTIN AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| WO-2019193159-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Universität Wien (AT) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | SLC9A1, SLC9A3, SLC5A1 | VCAM1 1603/4885KMT2A 3544/4885SLC10A6 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.